77 research outputs found
The cancer patient and cardiology
Advances in cancer treatments have improved clinical outcomes, leading to an increasing population of cancer survivors. However, this success is associated with high rates of short- and long-term cardiovascular (CV) toxicities. The number and variety of cancer drugs and CV toxicity types make long-term care a complex undertaking. This requires a multidisciplinary approach that includes expertise in oncology, cardiology and other related specialties, and has led to the development of the cardio-oncology subspecialty. This paper aims to provide an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long-term follow-up strategies for patients at risk of cancer therapy-related cardiotoxicities. Research to better define strategies for early identification, follow-up and management is highly necessary. Although the academic cardio-oncology community may be the best vehicle to foster awareness and research in this field, additional stakeholders (industry, government agencies and patient organizations) must be involved to facilitate cross-discipline interactions and help in the design and funding of cardio-oncology trials. The overarching goals of cardio-oncology are to assist clinicians in providing optimal care for patients with cancer and cancer survivors, to provide insight into future areas of research and to search for collaborations with industry, funding bodies and patient advocates. However, many unmet needs remain. This document is the product of brainstorming presentations and active discussions held at the Cardiovascular Round Table workshop organized in January 2020 by the European Society of Cardiology.</p
Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents
Anthracyclines : molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
The clinical use of anthracyclines like doxorubicin and daunorubicin can be viewed as a sort of double-edged sword. On the one hand, anthracyclines play an undisputed key role in the treatment of many neoplastic diseases; on the other hand, chronic administration of anthracyclines induces cardiomyopathy and congestive heart failure usually refractory to common medications. Second-generation analogs like epirubicin or idarubicin exhibit improvements in their therapeutic index, but the risk of inducing cardiomyopathy is not abated. It is because of their janus behavior (activity in tumors vis-\ue0-vis toxicity in cardiomyocytes) that anthracyclines continue to attract the interest of preclinical and clinical investigations despite their longer-than-40-year record of longevity. Here we review recent progresses that may serve as a framework for reappraising the activity and toxicity of anthracyclines on basic and clinical pharmacology grounds. We review 1) new aspects of anthracycline-induced DNA damage in cancer cells; 2) the role of iron and free radicals as causative factors of apoptosis or other forms of cardiac damage; 3) molecular mechanisms of cardiotoxic synergism between anthracyclines and other anticancer agents; 4) the pharmacologic rationale and clinical recommendations for using cardioprotectants while not interfering with tumor response; 5) the development of tumor-targeted anthracycline formulations; and 6) the designing of third-generation analogs and their assessment in preclinical or clinical settings. An overview of these issues confirms that anthracyclines remain "evergreen" drugs with broad clinical indications but have still an improvable therapeutic index
The hail-nets against Codling moth and their influence on the behavior of moth species harmful to the pear tree in Emilia-Romagna (Italy)
Codling moth (Lepidoptera, Tortricidae) is the most severe universal pest of apple and pear. In all commercial orchards the fruit have to be protected until the harvest. The insecticides are the main control tool and in Emilia-Romagna (Italy) the number of treatments varies from 8 to 12 per year. The current available insecticides are more specific, less toxic to humans and beneficial than earlier ones, but an effective biological control has not been possible yet, so the main control alternatives are mostly based on PMD (Pheromone Mating Disruption) and CpGV (Cydia pomonella) Granulosis Virus) use, although the efficacy depends on the population level, number of generation and treated surface. The use of hail-nets recently proposed seems to give very interesting results against C. pomonella as injured fruits, so some trials were carried out to investigate the reason of this change in codling moth, and other species frequently presents on pome fruits orchards, behaviour
- …